EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials

Maierdan Palihati iD, Jeeban Paul Das, Randy Yeh, Kathleen Capaccione

Tomography · 28.07.2025 · 11 (8) · 83

DOI: 10.3390/tomography11080083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tomography, online erschienen am 28.07.2025. Verfasst von Maierdan Palihati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Columbia University Irving Medical Center, 622 W 168th St., New York, NY 10032, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Radiopharmaceuticals, Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted radioligand therapy (RLT) is an emerging field in anticancer therapeutics with great potential across tumor types and stages of disease. While much progress has focused on agents targeting somatostatin receptors and prostate-specific membrane antigen (PSMA), the same advanced radioconjugation methods and molecular targeting have spurred the development of numerous theranostic combinations for other targets. A number of the most promising agents have progressed to clinical trials and are poised to change the landscape of positron emission tomography (PET) imaging. Here, we present recent data on some of the most important emerging molecular targeted agents with their exemplar clinical images, including agents targeting fibroblast activation protein (FAP), hypoxia markers, gastrin-releasing peptide receptors (GRPrs), and integrins. These radiopharmaceuticals share the promising characteristic of being able to image multiple types of cancer. Early clinical trials have already demonstrated superiority to 18F-fluorodeoxyglucose (18F-FDG) for some, suggesting the potential to supplant this longstanding PET radiotracer. Here, we provide a primer for practicing radiologists, particularly nuclear medicine clinicians, to understand novel PET imaging agents and their clinical applications, as well as the availability of companion targeted radiotherapeutics, the status of their regulatory approval, the potential challenges associated with their use, and the future opportunities and perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyRadiopharmaceuticalsNeoplasmsMolecular Targeted TherapyHumansReceptors, BombesinClinical Trials as Topic

Stichwörter der Autor:innen

clinical trialsfibroblast activation protein (FAP)gastrin-releasing peptide receptors (GRPrs)hypoxiaintegrinsradiopharmaceuticals

Substanzen

RadiopharmaceuticalsReceptors, Bombesin

Autor:innen und Institutionen

  • Department of Radiology, Columbia University Irving Medical Center, 622 W 168th St., New York, NY 10032, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Maierdan Palihati

Förderung

  • NCI NIH HHS

Zitieren

APA

Palihati, M., Das, J. P., Yeh, R., & Capaccione, K. (2025). Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. Tomography, 11(8), 83. https://doi.org/10.3390/tomography11080083

Vancouver

Palihati M, Das JP, Yeh R, Capaccione K. Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. Tomography. 2025;11(8):83. doi:10.3390/tomography11080083

BibTeX
@article{Palihati2025,
  author = {Palihati, Maierdan and Das, Jeeban Paul and Yeh, Randy and Capaccione, Kathleen},
  title = {Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials},
  journal = {Tomography},
  year = {2025},
  volume = {11},
  number = {8},
  pages = {83},
  doi = {10.3390/tomography11080083}
}
Kostenlos starten →